妖股天山生物(300313.SZ)大跌14.5% 或涉嫌虛構客户
格隆匯9月23日丨近期被推至風口浪尖的天山生物(300313.SZ)繼昨日復牌幾近跌停後,今日繼續大跌,半日跌14.5%報23.71元,較最高價34.66元下跌31.6%,最新總市值74億元。從8月下旬開始,天山生物股價連續暴漲,最大漲幅一度接近5倍,被稱為創業板改革後的“第一妖股”。9月21日晚間,證監會發公告稱對天山生物有關異常交易立案調查。然而,“妖股”天山生物的異常之處可能並不止於股價。據清流工作室,天山生物可能涉嫌虛構客户。在其披露的2018年、2019年年報中,存在至少兩名客户的銷售數據打架、同時客户工作人員稱“與天山生物沒有業務往來”等情形。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.